Effective treatment of spasticity using dronabinol in pediatric palliative care

European Journal of Paediatric Neurology

Volumn 20, Issue 6, 2016, Pages 898-903

  Kuhlen, Michaela ^a   Hoell, Jessica I ^a   Gagnon, Gabriele ^a   Balzer, Stefan ^a   Oommen, Prasad T ^a   Borkhardt, Arndt ^a   Janßen, Gisela ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Dronabinol; Pediatric palliative care patients; Spasticity

Indexed keywords

BACLOFEN; DIPYRONE; DRONABINOL; IBUPROFEN; MORPHINE; TILIDINE; TIZANIDINE; TRAMADOL;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HOME CARE; HUMAN; MALE; MEDICAL RECORD REVIEW; NEUROLOGIC DISEASE; OPEN STUDY; PAIN; PALLIATIVE THERAPY; PEDIATRICS; PRIORITY JOURNAL; RESTLESSNESS; RETROSPECTIVE STUDY; SPASTICITY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; YOUNG ADULT; COMPLICATION; DRUG EFFECTS; DRUG RESISTANCE; INFANT; MUSCLE SPASTICITY; MUSCLE TONE; NEURODEGENERATIVE DISEASES; PRESCHOOL CHILD; PROCEDURES; TERMINAL CARE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; DRUG RESISTANCE; FEMALE; HUMANS; INFANT; MALE; MUSCLE SPASTICITY; MUSCLE TONUS; NEURODEGENERATIVE DISEASES; PALLIATIVE CARE; RETROSPECTIVE STUDIES; TERMINAL CARE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84989260428     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2016.07.021     Document Type: Article

References (29)

1. 1 Bhargava, H.N., Potential therapeutic applications of naturally occurring and synthetic cannabinoids. Gen Pharmacol 9:4 (1978), 195–213.
2. 2 Grotenhermen, F., Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:4 (2003), 327–360.
3. 3 Borgelt, L.M., et al. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 33:2 (2013), 195–209.
4. 4 Robson, P.J., Therapeutic potential of cannabinoid medicines. Drug Test Anal 6:1–2 (2014), 24–30.
5. 5 Leung, L., Cannabis and its derivatives: review of medical use. J Am Board Fam Med 24:4 (2011), 452–462.
6. 6 Novotna, A., et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R))), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18:9 (2011), 1122–1131.
7. 7 Oreja-Guevara, C., Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Rev Neurother 12:4 Suppl. (2012), 3–8.
8. 8 Wissel, J., et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol 253:10 (2006), 1337–1341.
9. 9 Devinsky, O., et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55:6 (2014), 791–802.
10. 10 Huestis, M.A., Human cannabinoid pharmacokinetics. Chem Biodivers 4:8 (2007), 1770–1804.
11. 11 Collin, C., et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32:5 (2010), 451–459.
12. 12 Corey-Bloom, J., et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. Can Med Assoc J 184:10 (2012), 1143–1150.
13. 13 Flachenecker, P., Henze, T., Zettl, U.K., Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 72:1–2 (2014), 95–102.
14. 14 Patti, F., et al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurology, Neurosurg Psychiatry, 2016 May 9, 10.1136/jnnp-2015-312591.
15. 15 Hauer, J.M., Solodiuk, J.C., Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. J Palliat Med 18:5 (2015), 453–456.
16. 16 Collin, C., et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 14:3 (2007), 290–296.
17. 17 Zajicek, J.P., et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76:12 (2005), 1664–1669.
18. 18 Zajicek, J., et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:9395 (2003), 1517–1526.
19. 19 Meier, M.H., et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U. S. A 109:40 (2012), E2657–E2664.
20. 20 Di Marzo, V., Centonze, D., Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes. CNS Neurosci Ther 21:3 (2015), 215–221.
21. 21 Finniss, D.G., et al. Biological, clinical, and ethical advances of placebo effects. Lancet 375:9715 (2010), 686–695.
22. 22 Pryce, G., Baker, D., Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 150:4 (2007), 519–525.
23. 23 Vaney, C., et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 10:4 (2004), 417–424.
24. 24 Rasmussen, L.A., Gregoire, M.C., Challenging neurological symptoms in paediatric palliative care: an approach to symptom evaluation and management in children with neurological impairment. Paediatr Child Health 20:3 (2015), 159–165.
25. 25 http://www.fachinfo.de.
26. 26 Wang, T., et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ 178:13 (2008), 1669–1678.
27. 27 Wade, D.T., et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12:5 (2006), 639–645.
28. 28 Bohannon, R.W., Smith, M.B., Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:2 (1987), 206–207.
29. 29 Gracies, J.M., et al. Reliability of the Tardieu Scale for assessing spasticity in children with cerebral palsy. Arch Phys Med Rehabil 91:3 (2010), 421–428.